Pink Sheet Podcast: Data Protection, Price Negotiation, Warning Letters, Amylyx At ICER
Executive Summary
Pink Sheet reporter reviews recent stories on US FDA concerns about the EU data protection regulation, the US enacting the Medicare price negotiation law, warning letters sent to Emergent BioSolutions and ImprimisRx, and Amylyx’s ALS drug going in front of the Institute for Clinical and Economic Review.
You may also be interested in...
AstraZeneca’s Nirsevimab: US FDA Wants Input On How It Would Fit With Pediatric RSV Vaccines
Proposed RSV prevention treatment for infants and neonates showed efficacy with few safety concerns, but with pediatric vaccines in development, FDA wants the Antimicrobial Drugs Advisory Committee to discuss what data would be needed to determine appropriate use in vaccinated infants and mothers.
Novavax Readying Multiple COVID-19 Vaccine Candidates To Ensure Fall Availability
CBER’s Marks said US FDA is working with Novavax on manufacturing to allow its protein-based vaccine to be ready for a fall roll-out. After some concerns about international coordination, multiple regulators seem to be settling on a monovalent approach for fall vaccinations.
US FDA Looks To Assure Advisory Committees' Subject Expertise With More Temporary Members
Reform efforts in CDER include ensuring expertise is specific to the issues being discussed, which may mean more temporary voting members on advisory committees.